Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Other Events

Item 8.01Other Items.

On December 1, 2016 in an oral presentation at the 28th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics in Munich, Germany (the EORTC-NCI-AACR Symposium),
Blueprint Medicines Corporation (the Company) presented initial
data from the dose escalation stage of its ongoing Phase 1
clinical trial evaluating BLU-285 for the treatment of advanced
gastrointestinal stromal tumors (GIST). BLU-285 is an orally
available, potent and highly selective inhibitor that targets
D842V mutant PDGFR and Exon 17 mutant KIT.A copy of the slide
presentation is filed as Exhibit 99.1 to this Current Report on
Form 8-K and incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, including, without
limitation, statements regarding plans and timelines for the
clinical development of BLU-285; and the Companys ability to
implement its clinical development plans for BLU-285 for the
treatment of advanced GIST. The words may, will, could, would,
should, expect, plan, anticipate, intend, believe, estimate,
predict, project, potential, continue, target and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this Current
Report on Form 8-K are based on managements current expectations
and beliefs and are subject to a number of risks, uncertainties
and important factors that may cause actual events or results to
differ materially from those expressed or implied by any
forward-looking statements contained in this Current Report on
Form 8-K, including, without limitation, risks and uncertainties
related to the delay of any current or planned clinical trials or
the development of BLU-285; the Companys advancement of multiple
early-stage efforts; the Companys ability to successfully
demonstrate the efficacy and safety of its drug product
candidates; the preclinical and clinical results for the Companys
drug product candidates, which may not support further
development of such drug product candidates; and actions of
regulatory agencies, which may affect the initiation, timing and
progress of clinical trials; the Companys ability to develop and
commercialize companion diagnostics for its current and future
drug candidates, including companion diagnostics for BLU-285 with
QIAGEN Manchester Limited; and the success of the Companys rare
genetic disease collaboration with Alexion Pharma Holding and its
cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd
and Hoffmann-La Roche Inc. These and other risks and
uncertainties are described in greater detail in the section
entitled Risk Factors in the Companys Quarterly Report on Form
10-Q for the quarter ended September 30, 2016, as filed with the
Securities and Exchange Commission (SEC) on November 10, 2016,
and other filings that Blueprint Medicines may make with the SEC
in the future. Any forward-looking statements contained in this
Current Report on Form 8-K represent the Companys views only as
of the date hereof and should not be relied upon as representing
its views as of any subsequent date. The Company explicitly
disclaims any obligation to update any forward-looking
statements.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Blueprint Medicines Corporation (NASDAQ:BPMC) Recent Trading Information

Blueprint Medicines Corporation (NASDAQ:BPMC) closed its last trading session down -1.75 at 27.62 with 316,481 shares trading hands.